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BACKGROUND Simultaneous mitral regurgitation (MR) is common in
patients undergoing percutaneous aortic valve implantation (TAVI),
but its impact is controversial. Albeit multidetector computed to-
mography (MDCT) is routinely performed to TAVI candidates in many
centers, the potential usefulness of this tool to decide which patients
with dual valvulopathy may beneﬁt from isolated TAVI is unknown.
METHODS We analyzed 1110 patients from 6 centers treated with
TAVI according to the baseline degree of their MR. All clinical and
procedural variables were prospectively recorded. An off-line analysis
of echocardiographic and MDCT images, including annulus and leaf-
lets semi-quantitative analysis of calciﬁcation, was performed in order
to determine predictors of MR improvement. Multivariate analysis
was performed to determine predictors of MR improvement and of
mortality.
RESULTS Mean age was 80.57 years, and mean STS-score 7.25.1%.
Patients with moderate-to-severe MR (n¼177, 15.9%) were more
frequently males (57.6 vs. 38.9%, p<0.001), considered of functional
etiology in 37.3% vs. 27.5%, p¼0.009, and with lower degree of
annulus and leaﬂets calciﬁcation as estimated by MDCT (p<0.001 for
both). They required more frequently hemodynamic support during
the procedure (9.5 vs. 2.9%, p<0.001) despite similar left ventricular
ejection fraction, and presented higher rate of new-onset atrial
ﬁbrillation (NOAF) (17.9 vs. 9.8%, p¼0.003). Functional NYHA class
was similar in the follow-up but both in-hospital (9 vs 4.6%) and 6-
month mortality (33.9 vs. 9.4%) were higher (p¼0.016 and p<0.001,
respectively). Among them, the degree of MR improved in 103 pa-
tients (58.2%) with presence of calciﬁcation in the leaﬂets and the
mitro-aortic junction as determined by MDCT, left bundle branch
block at discharge, new permanent pacemaker, NOAF, and elevated
pulmonary pressure as the main independent predictors of lack of
improvement. Mortality at 6-month follow-up was 13.1% with valve
embolization, absence of improvement of MR, STS score and LBBB at
discharge as the main independent predictors of mortality.
CONCLUSIONS Simultaneous moderate-severe MR was not uncom-
mon in patients who underwent TAVI. Conduction disturbances,
calciﬁcation of mitral apparatus and mitro-aortic junction by MDCT,
NOAF, and elevated pulmonary pressure determined lack of
improvement in the degree of MR after TAVI. In more than half of the
patients there was an improvement in the degree of MR; nevertheless,
moderate-severe MR at baseline had an impact in early and late
mortality.
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BACKGROUND Despite the lack of strong medical evidence percuta-
neous mitral valve repair (PMVR) using the MitraClip-system is
increasingly performed in patients with functional mitral regurgita-
tion. Retrospective data in high-risk patients conﬁrm its validity but
prospective data from large registries are still lacking. Herein, we
report preliminary results of the prospective Swiss nationwide
investigator-initiated MitraClip registry (MitraSwiss).
METHODS Among the patients included in the MitraSwiss registry we
analyzed those presenting with either ischemic-function or pure
functional MR in the clinical context of advanced heart failure. In all
patients PMVR was performed under general anesthesia in the cath-
lab or hybrid operating room with ﬂuoroscopic and transesophageal
echocardiography guidance.
RESULTS From 2011 until 2015, a total of 249 patients (corresponding
to 53% of the entire registry population) with functional MR (53%
ischemic, 47% nonischemic etiology) and a median left ventricular
ejection fraction (LVEF) of 35% (range 26-47%) were included in the
current analysis. Acute improvement (to MR grade 1þ or 2þ) was
achieved in 87%, and conﬁrmed at 6 months in 76% of the patients
with 74% still NYHA functional class I or II These results did not differ
substantially when comparing them to the entire registry population.
6 months survival (91.1%; 95%CI: 86.8-94.1%) trended to be lower
compared to the entire registry population, particularly for patients
with non-ischemic origin, which resulted a signiﬁcant predictor of
mortality (HR: 2.32; 95%CI 1.5-3.6). More details of the ongoing anal-
ysis and 12 months follow-up data will be available at the time of the
meeting.
Table. Baseline characteristics of the patients with functional MR:Parameter median (IQR)LVEF (%) 35 (26-47)LVEDV (ml) 172 (125-224)LVESV (ml) 118 (85-165)Grad. RV-RA (mmHg) 40 (31-53)6MWD (m) 325 (225-390)MLWHF score (pts) 37 (25-51)nt-proBNP (pg/ml) 3911 (1832-7205)Legend: LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left
ventricular end-systolic volume; Grad. RV-RA: pressure gradient measured between right ventricle and right
atrium using the continuous wave Doppler; 6MWD: 6 minutes walking distance; MLWHF: Minnesota living
with heart failure score for the assessment of the quality of life; nt-proBNP: n-terminal brain natriuretic
peptide
CONCLUSIONS PMVR in patients with functional MR provide similar
improvement of MR grade and symptoms at short term and after 6
months as compared to the entire MitraSwiss registry population.
Further insights and 12 months data will be available for the time of
the meeting.
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BACKGROUND Paravalvular regurgitation is an uncommon yet
serious complication associated with surgical prosthetic valve im-
plantation. Studies show an incidence between 3% - 6% of para-
valvular prosthetic leak with clinical manifestations. Surgical repair is
the best treatment for these cases. However in high risk patients,
percutaneous leak closure seems to be a promising and less invasive
option. There are few studies in the literature comparing the two
treatment options.
METHODS A retrospective, observational study of 35 patients with
diagnosis of paravalvular prosthetic regurgitation with clinical
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anemia). The patients were followed up for 23 months, from January
of 2011 to December of 2013. All the patients went through surgical
repair or percutaneous leak closure (Amplatzer AVP II). Primarily, we
analyzed the epidemiological data related with paravalvular pros-
thetic regurgitation; sequentially the patients were divided into two
treatment groups, percutaneous leak closure or surgical repair. Finally
we analyzed the clinical outcomes during hospitalization and up to 1
year.
RESULTS The median age at the time of diagnosis was 54  14 years,
71.4% of whom were men. The mitral valve had a higher incidence of
paravalvular leak (60%) and was more common in biological valve
prostheses (51.4%). We report 10 patients (28.6%) in the percuta-
neous leak closure group, and 25 patients (71.4%) in the surgical
repair group. The percutaneous leak closure group had patients of
higher risk, older patients (63  13 vs. 54  14, p¼0.011), higher
prevalence of diabetes (30% vs. 0%, p¼ 0.018), increase number of
previous surgeries (2.6  1 vs. 1.72  0.7, p¼0.04) and lower creati-
nine clearance (Cockcroft-Gault Equation) (72  38 vs. 90  38,
p¼0.07). The clinical presentation was heart failure class III by New
York Heart Association classiﬁcation (40%) and hemolytic anemia
(42%). During hospitalization we report 74.3% of complications in
the both groups, the surgical repair group had more bleeding com-
plications (48% vs. 30%, p¼0.45) and infection (36% vs. 10%,
p¼0.21), however this complications did not have statistical signiﬁ-
cance when clinical outcomes were analyzed between the groups. At
1 year follow up, mortality (0% vs. 20%, p¼0.08) did not have sta-
tistical signiﬁcance.
CONCLUSIONS Symptomatic paravalvular prosthetic regurgitation is
an uncommon yet serious complication more associated with mitral
valve and biological prostheses. Surgical repair is the best treatment
option; however percutaneous leak closure is a promising treatment
in high risk patients. There is a need of development of new devices
for this pathology. Our study showed no difference in clinical out-
comes between the two groups; however we did not have a large
number of patients.
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BACKGROUND The Use of retrograde femoral access to close Mitral
Paravalvular Leakage (MPVL) in patients with the combination of
aortic and mitral metallic prostheses has considered contraindicated.
The aim of this study was to assess the safety and feasibility of
Percutaneous Closure of MPVL in patients with double aortic and
metallic prostheses.
METHODS Consecutive patients with double prosthesis (DP) who
underwent percutaneous MPVL closure in our institution were
included. Anterograde and retrograde approach consisting of crossing
the wire across the aortic prosthesis in order to access and cross the
perivalvular mitral leak were used. Arterious venous loop (AVL) were
also performed in all cases but one. The device used in all in-
terventions were Amplatzer Vascular Plug III. Immediate and mid-
term follow-up results were analyzed.
RESULTS From February 2009 to December 2014, 56 patients under-
went MPVL in our institution. Twenty ﬁve patients (44.6%) had
double prosthetic mitral and aortic valve (DP). Mean age was 69 11.
40% were male. The mean clinical follow up was 416.5323.1 days
Retrograde approach with AVL was performed in 17 patients (68%). All
procedures were hemodynamically well tolerated. Technical success
rates were 88%, (2 patients needed two procedures). One patient had
device embolization that was percutaneously captured and a second
device was successfully implanted in the same procedure and 1 pa-
tient needed emergency surgery due to disc interference. At follow-up
50% of the patients presented signiﬁcant NYHA functional classimprovement. Seven patients (28%) died during follow-up due to
persistent cardiac failure.
CONCLUSIONS Percutaneous Closure of MPVL in patients with dou-
ble aortic and mitral prosthesis can be done safely considering few
tips are taking into consideration during the procedure.
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BACKGROUND Percutaneous treatment of mitral regurgitation (MR)
is an option for patients facing a high operative risk. The inﬂuence of
percutaneous edge-to-edge mitral valve repair (PMVR) on the mitral
valve (MV) geometry is not yet clearly understood. We herein in
present a novel four-dimensional echocardiography based computa-
tional model to assess morphologic MV changes during the complete
cardiac cycle before and after edge-to-edge MV repair.
METHODS Twenty-eight consecutive patients (mean age 77  8 years)
underwent elective PMVR for mitral regurgitation with the MitraClip
device. Periprocedural RT3DTEE data were analyzed using a semi-
automated MV modeling software (eSie Valves) focusing on MV
oriﬁce area, commissural diameter, antero-posterior diameter, ante-
rolateral-posteriomedial diameter, annular area, annular circumfer-
ence and annular height throughout the entire cardiac cycle in 10%
steps.
RESULTS PMVR led to a reduction in MV oriﬁce area (4.61.9 and
1.50.5 cm2; P<0,001) and a postponed opening of the MV leaﬂets in
diastole (20 and 35% of cardiac cycle). The anterior-posterior diameter
was reduced signiﬁcantly (34.55.0 and 31.93.8 mm; P<0.001)
whereas the anterolateral-posteromedial and commissural diameter
increased in diastole (39.75.0 and 42.34.6 mm; P<0,001 and
38.84.9 and 41.04.3 mm; P<0,001), respectively. No signiﬁcant
changes were detected for annular area, annular circumference and
annular height.
CONCLUSIONS Four-dimensional analysis after PMVR depicts sig-
niﬁcant changes in the MV geometry. Furthermore not yet detected
changes of MV opening and closing are presented. To the best of our
knowledge this is the ﬁrst 4-dimensional analysis of MV before and
after PMVR.
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